Head to Head Survey: Cerebain Biotech (OTCMKTS:CBBT) vs. AbCellera Biologics (NASDAQ:ABCL)

Cerebain Biotech (OTCMKTS:CBBT) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerebain Biotech and AbCellera Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerebain Biotech	0	0	0	0	N/A
AbCellera Biologics	0	1	5	0	2.83

AbCellera Biologics has a consensus target price of $14.20, suggesting a potential upside of 444.06%. Given AbCellera Biologics’ higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Cerebain Biotech.

Valuation & Earnings

This table compares Cerebain Biotech and AbCellera Biologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerebain Biotech	N/A	N/A	N/A	N/A	N/A
AbCellera Biologics	$33.05 million	23.22	-$146.40 million	($0.52)	-5.02

Cerebain Biotech has higher earnings, but lower revenue than AbCellera Biologics.

Insider & Institutional Ownership

61.4% of AbCellera Biologics shares are held by institutional investors. 32.5% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cerebain Biotech and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cerebain Biotech	N/A	N/A	N/A
AbCellera Biologics	-463.77%	-13.40%	-10.44%

Summary

AbCellera Biologics beats Cerebain Biotech on 5 of the 8 factors compared between the two stocks.

About Cerebain Biotech

Cerebain Biotech Corp. is a biomedical company, which engages in the creation and clinical development of a minimally invasive implantable device. It focuses on the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The company was founded on December 18, 2007 and is headquartered in Costa Mesa, CA.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.